Why Is Broadcom Stock Rising Today?

Broadcom Inc. (NASDAQ: AVGO) shares are moving Tuesday after several analysts raised their price targets on the stock.

Broadcom Inc. (NASDAQ:AVGO) shares are moving Tuesday after several analysts raised their price targets on the stock.

What To Know: Multiple analysts lifted price targets for Broadcom, ranging from $820 to $890. This is auspicious timing for the company as the broader technology sector has benefitted from the recent AI-related surge from Nvidia Corp.

Here’s a look at the analyst changes from Tuesday.

  • Keybanc maintained Broadcom with an Overweight and raised the price target from $720 to $820.
  • Evercore ISI Group maintained Broadcom with an Outperform and raised the price target from $725 to $850.
  • BMO Capital maintained Broadcom with an Outperform and raised the price target from $750 to $890.

The analyst updates come just days ahead of Broadcom’s second-quarter earnings, due June 1. According to estimates from Benzinga Pro, Broadcom is expected to report earnings of $10.08 per share on quarterly revenue of $8.7 billion.

Related Link: What’s Going On With Microsoft Stock Tuesday

AVGO Price Action: Shares of AVGO were up 1.89% at $828.11 at the time of publication, according to Benzinga Pro.

Image by Recklessstudios from Pixabay

Total
0
Shares
Related Posts
Read More

Calliditas Therapeutics Announced Primary Endpoint Successfully Met In Phase 3 NefIgArd Trial Evaluating Nefecon In IgA Nephropathy

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon (TARPEYO®/Kinpeygo® (budesonide) delayed release capsules) versus placebo in patients with primary IgA nephropathy (IgAN).

CALT